<DOC>
	<DOCNO>NCT00145704</DOCNO>
	<brief_summary>The purpose project evaluate hypothesis bisphosphonate treatment give growth hormone deficient patient ( regardless current growth hormone replacement therapy status without change status ) significantly increase total body bone mineral density eighteen month period treatment combine calcium Vitamin D compare calcium Vitamin D treatment alone .</brief_summary>
	<brief_title>Study Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density</brief_title>
	<detailed_description>Adult patient Dexa scan ( bone scan ) z-scores &lt; -1.0 ( mean low bone density ) least one site select randomization . All patient qualify randomization undergo baseline bloodwork serum bone specific alkaline phosphatase ( BSAP ) n-terminal telopeptides collagen ( NTX ) level . Recent bloodwork obtain part ongoing long-term Pediatric Oncology and/or Endocrine clinic follow-up evaluation review exclude baseline correctable confounding cause osteopenia ( low bone density ) . All woman childbearing potential pregnancy test . For patient already growth hormone replacement therapy , growth hormone administer per standard care , standard dose range adjust base upon IGF-1 ( Insulin like growth factor ) monitoring . Those patient currently receive growth hormone replacement therapy place therapy part study . Patients growth hormone replacement therapy randomize block design two treatment arm assure equal number treatment arm . The bisphosphonate utilize provide Arm II patient charge . All Arm II patient receive bisphosphonate regimen , Risedronate 35 mg per oral weekly 18 month . All patient arm I II also receive Vitamin D ( 400 IU p.o . daily ) calcium carbonate ( 500 mg p.o . twice daily ) free charge eighteen month .</detailed_description>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<mesh_term>Risedronate Sodium</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Growth hormone deficiency complication treatment pediatric malignancy Dexa ( bone densitometry ) zscores &lt; 1.0 least one site Dexa ( bone densitometry ) zscores &lt; 1.0 least one site Subjects &lt; 18 year old Pregnant lactating patient Any contraindication unwillingness consider bisphosphonate treatment Inability unwillingness undergo bone density evaluation Other correctable cause decrease bone mineral density</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>osteopenia</keyword>
	<keyword>growth hormone deficiency</keyword>
	<keyword>pediatric malignancy</keyword>
</DOC>